DOCSLIB.ORG

Gene Targeting Therapies (Roy Alcalay)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Recent Developments in Gene - Targeted Therapies for Parkinson’s Disease Roy Alcalay, MD, MS Alfred and Minnie Bressler Associate Professor of Neurology Division of Movement Disorders Columbia University Medical Center Disclosures Funding: Dr. Alcalay is funded by the National Institutes of Health, the DOD, the Michael J. Fox Foundation and the Parkinson’s Foundation. Dr. Alcalay receives consultation fees from Genzyme/Sanofi, Restorbio, Janssen, and Roche. Gene Localizations Identified in PD Gene Symbol Protein Transmission Chromosome PARK1 SNCA α-synuclein AD 4q22.1 PARK2 PRKN parkin (ubiquitin ligase) AR 6q26 PARK3 ? ? AD 2p13 PARK4 SNCA triplication α-synuclein AD 4q22.1 PARK5 UCH-L1 ubiquitin C-terminal AD 4p13 hydrolase-L1 PARK6 PINK1 PTEN-induced kinase 1 AR 1p36.12 PARK7 DJ-1 DJ-1 AR 1p36.23 PARK8 LRRK2 leucine rich repeat kinase 2 AD 12q12 PARK9 ATP13A2 lysosomal ATPase AR 1p36.13 PARK10 ? ? (Iceland) AR 1p32 PARK11 GIGYF2 GRB10-interacting GYF protein 2 AD 2q37.1 PARK12 ? ? X-R Xq21-q25 PARK13 HTRA2 serine protease AD 2p13.1 PARK14 PLA2G6 phospholipase A2 (INAD) AR 22q13.1 PARK15 FBXO7 F-box only protein 7 AR 22q12.3 PARK16 ? Discovered by GWAS ? 1q32 PARK17 VPS35 vacuolar protein sorting 35 AD 16q11.2 PARK18 EIF4G1 initiation of protein synth AD 3q27.1 PARK19 DNAJC6 auxilin AR 1p31.3 PARK20 SYNJ1 synaptojanin 1 AR 21q22.11 PARK21 DNAJC13 8/RME-8 AD 3q22.1 PARK22 CHCHD2 AD 7p11.2 PARK23 VPS13C AR 15q22 Gene Localizations Identified in PD Disorder Symbol Protein Transmission Chromosome PD GBA β-glucocerebrosidase AD 1q21 SCA2 ATXN2 ataxin-2 AD 12q23-24.1 SCA17 TBP TATA-binding protein AD 6q27 DYT5a GCH1 GTP cyclohydrolase 1 AD 4q22.1 DYT5b TH tyrosine hydroxylase AR 11p15.5 RIT2 locus via GWAS study GTPase ? 18q12.3 PDXK Pyridoxal kinase ? 21q22.3 HLA-DRA Human leukocyte antigen ? 6p21.3 SYNE1 Synaptic nuclear protein 1 ? 6q25 SLC6A3 Dopamine transporter AR 5p15.3 SLC30A10 Mn transporter AR 1q41 SPG11 spatacsin AR 15p21.1 FTD FUS Fusion gene AD 16p11.2 FTD/MND C9ORF72 ? AD 9p21 PD/ALS ANG angiogenin ? 14q11.2 PD DNAJC1 RME-8 AD 3q22.1 Juv PD SYNJ1 synaptojanin 1 AR 21q22.11 Juv PD DNAJC6 auxilin AR 1p31.3 Infant PD SLC18A2 VMAT2 AR 10q25 Frequency of Known Mutations at Columbia University (Source Studies: CORE-PD; Spot) • SNCA: exceedingly rare (2 confirmed cases) • PRKN: common when age-at-onset below 30 • LRRK2: 1% of the entire center; 15% of Ashkenazi Jews (AJ) with PD • GBA: 5% of the entire center; 20% of AJ with PD Genetics Risks for PD by Frequency and Risk A: Rare variants. Rare and highly penetrant B: Common variants. Low penetrance C: Intermediate variants. Intermediate penetrance and frequency Gene-Targeted Therapies for PD • Rare variants – future patient customized therapies, e.g., Kim el al 2019 • Common variants – common targets, e.g., immune therapies targeting a-synuclein • Intermediate variants – most advanced precision medicine for PD GBA LRRK2 Outline • LRRK2-related clinical trials – Epidemiology and Mechanism – Specific studies • GBA-related clinical trials – Epidemiology and Mechanism – Specific studies • Common questions and challenges Outline • LRRK2-related clinical trials – Epidemiology and Mechanism – Specific studies • GBA-related clinical trials – Epidemiology and Mechanism – Specific studies • Common questions and challenges LRRK2 Epidemiology • 1% of sporadic PD and 4% of familial PD carry LRRK2 mutations (Healy, 2008) • 40% of North African Berbers with PD (Lesage, 2006) • 14% of Ashkenazi Jews (AJ) with PD (Ozelius, 2006; Alcalay, 2013) • Gender distribution in LRRK2 is 50/50 (Orr-Urtreger, 2007) • Penetrance estimation by age 80 (Lee, 2017): – 25% AJ – 42.5% Non-AJ LRRK2 Kinase Activity • LRRK2 substrates: – Rab GTPases (Steger, 2016) – Autophosphorylation. (e.g., Serine 1292 residue) (Sheng, 2012) • Most, but not all, LRRK2 mutations are associated with increased kinase activity LRRK2 Kinase Activity • LRRK2 is abundantly expressed in the kidneys, lungs, pancreas, and certain cell types of the immune system (Schapansky, 2015) • LRRK2 inhibitors were developed promptly after the discovery of LRRK2, but clinical trials were postponed for concern for renal and/or pulmonary side-effects (lamellar bodies) Battista et al., 2018 LRRK2 in Urine Exosomes of G2019S Carriers with and without PD Frazer et al., Neurology. 2016 Urine BMP Levels by LRRK2 and PD Status Alcalay et al., 2019 LRRK2 in Idiopathic PD Di Maio, 2018 • Wildtype LRRK2 kinase activity is selectively enhanced in substantia nigra dopamine neurons in iPD. Outline • LRRK2-related clinical trials – Epidemiology and Mechanism – Specific studies • GBA-related clinical trials – Epidemiology and Mechanism – Specific studies DNL151 NCT04056689 • 2017: Phase I • 2020: Phase I-b – Enrollment: 34 people with PD with or without an LRRK2 mutations – Treatment: 3 doses for 28 days. – Primary outcome: comprises adverse events and laboratory tests, vital signs, ECG, or neurological exam. – Secondary outcomes: include pharmacokinetics, and LRRK2 and Rab10 phosphorylation in blood. – Status: The trial is delayed because of COVID-19. – Recruitment in Belgium, Netherlands, UK DNL201 NCT03710707 • 2018-2019: Phase Ib – Status: Completed – Enrollment: 29 PD patients with or without LRRK2 mutation – Treatment: Two doses • Primary outcomes: consisted of adverse events and abnormalities in laboratory tests, vital signs, ECG, or neurological exam. • Secondary outcomes: included pharmacokinetics, and LRRK2 and Rab10 phosphorylation. Also, BMP in urine. • In a January 2020 Denali announced that both doses achieved more than 50 percent inhibition of LRRK2 and Rab10 phosphorylation in blood, and improved BMP in urine BIIB094 NCT03976349 • Antisense oligonucleotide (ASO) • Binds the mRNA for LRRK2 and mediates its degradation. • 2019: Phase I safety trial – Enrollment: 62 participants, with or without a LRRK2 mutation – Treatment: Intrathecal injection, a single dose, multiple doses, or placebo. – Primary outcome: adverse events or serious adverse events for up to one year after injection. – Secondary outcomes: include pharmacokinetics of the ASO in blood. – Sites: 15 centers in Israel, North America, Norway, Spain and the U.K. Additional Studies • GSK NCT01424475 • Genentech • Merck • Pfizer Outline • LRRK2-related clinical trials – Epidemiology and Mechanism – Specific studies • GBA-related clinical trials – Epidemiology and Mechanism – Specific studies • Common questions and challenges Gaucher Disease • Common lysosomal storage disorder • Autosomal recessive: caused by mutations in glucocerebrosidase (GBA) • Leads to deficiency of the lysosomal enzyme Glucocerebrosidase (GCase) • Divided into three types: – Type 1 (non-neuronopathic) – Types 2 and 3 (neuronopathic) GBA/PD Epidemiology • 3% of PD patients carry either the N370S or the L444P GBA mutations (Sidransky, 2009) • 5-10% of PD patients carry a GBA mutation or variant (Gan-Or, 2015) • 35% of all Ashkenazi Jews (AJ) with PD are carriers of either GBA or LRRK2 mutations (Aharon-Peretz, 2004; Gan-Or, 2008; Clark 2008; Alcalay, 2010) • Penetrance estimation between 10-30% Gaucher Disease: Pathology Gaucher cells filled with glycosphingolipids accumulate in the reticuloendothelial system Glucocerebrosidase Pathway GBA/PD Mechanism: Loss or Gain? Gain of Function Loss of Function Biomarkers: GCase Activity • GCase activity is reduced in GBA carriers and Gaucher patients • GCase activity is reduced in autopsies of iPD cases, without GBA mutations (Gegg, 2012; Murphy, 2014; Clark, 2015) • Mildly reduced GCase activity peripherally in iPD compared to controls (Alcalay, 2015) • Among iPD, low GCase activity may be associated with faster disease progression (Alcalay, 2015) Outline • LRRK2-related clinical trials – Epidemiology and Mechanism – Specific studies • GBA-related clinical trials – Epidemiology and Mechanism – Specific studies • Common questions and challenges Ambroxol (Aim PD) NCT02941822 • Licensed in the EU as an over-the-counter drug (mucolytic). • Aim PD: – Design: Phase IIA prospective, single-center, open label – Treatment: Escalating dose up to 1.26g a day (x10 fold) – Primary outcome: GCase and ambroxol levels in blood and CSF – Secondary outcome: treatment related adverse events, pharmacodynamics and biomarkers – Other outcomes: performance on motor and cognitive scales Ambroxol (Aim PD) NCT02941822 - cont. • Enrollment: Recruited 17 PD patients (8 GBA-PD, 9 non- GBA PD) • Results: – Ambroxol levels in CSF was equal to 11% of blood serum levels. – CSF GCase protein increased (35%; P = .002) – CSF GCase activity reduced by 19% (P = 0.04) – CSF α-synuclein increased (13%; P = 0.01) Venglustat (GZ/SAR402671) NCT02906020 • Brain-penetrant inhibitor of glucosylceramide synthase • Clinical trials in Gaucher, Fabry, autosomal dominant polycystic kidneys, Tay-Sachs and PD • Phase I: drug levels in plasma and CSF increased in a dose-dependent fashion; plasma and CSF glucosylceramide levels declined by up to 75 percent (Peterscmitt et al., 2019). • In 2016, MOVES-PD launched Venglustat (GZ/SAR402671) NCT02906020 – cont. • Enrollment: 270 participants with GBA variants • Treatment: One year regimen of once-daily drug or placebo, plus two years of follow-up. • Primary outcome: Change from baseline to one year on the UPDRS Part II and III • Secondary outcomes: Change in other PD cognitive and motor outcomes • Status: The treatment phase planned to finish in Dec. 2020. Trial completion in 2023. LTI-291 NL7061 (NTR7299) • LTI-291 is a small-molecule activator of Gcase • Completed Phase Ib study
Recommended publications
  • Phosphorylation of Synaptojanin Differentially Regulates Endocytosis of Functionally Distinct Synaptic Vesicle Pools

    Phosphorylation of Synaptojanin Differentially Regulates Endocytosis of Functionally Distinct Synaptic Vesicle Pools

    8882 • The Journal of Neuroscience, August 24, 2016 • 36(34):8882–8894 Cellular/Molecular Phosphorylation of Synaptojanin Differentially Regulates Endocytosis of Functionally Distinct Synaptic Vesicle Pools X Junhua Geng,1* Liping Wang,1,2* Joo Yeun Lee,1,4 XChun-Kan Chen,1 and Karen T. Chang1,3,4 1Zilkha Neurogenetic Institute, 2Department of Biochemistry and Molecular Biology, and 3Department of Cell and Neurobiology, Keck School of Medicine, University of Southern California, Los Angeles, California 90089, and 4Neuroscience Graduate Program, University of Southern California, Los Angeles, California 90089 The rapid replenishment of synaptic vesicles through endocytosis is crucial for sustaining synaptic transmission during intense neuronal activity. Synaptojanin (Synj), a phosphoinositide phosphatase, is known to play an important role in vesicle recycling by promoting the uncoating of clathrin following synaptic vesicle uptake. Synj has been shown to be a substrate of the minibrain (Mnb) kinase, a fly homolog of the dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A); however, the functional impacts of Synj phosphorylation by Mnb are not well understood. Here we identify that Mnb phosphorylates Synj at S1029 in Drosophila. We find that phosphorylation of Synj at S1029 enhances Synj phosphatase activity, alters interaction between Synj and endophilin, and promotes efficient endocytosis of the active cycling vesicle pool (also referred to as exo-endo cycling pool) at the expense of reserve pool vesicle endocytosis. Dephosphorylated Synj, on the other hand, is deficient in the endocytosis of the active recycling pool vesicles but maintains reserve pool vesicle endocytosis to restore total vesicle pool size and sustain synaptic transmission. Together, our findings reveal a novel role for Synj in modulating reserve pool vesicle endocytosis and further indicate that dynamic phosphorylation and dephosphorylation of Synj differentially maintain endocytosis of distinct functional synaptic vesicle pools.
  • Computational Genome-Wide Identification of Heat Shock Protein Genes in the Bovine Genome [Version 1; Peer Review: 2 Approved, 1 Approved with Reservations]

    Computational Genome-Wide Identification of Heat Shock Protein Genes in the Bovine Genome [Version 1; Peer Review: 2 Approved, 1 Approved with Reservations]

    F1000Research 2018, 7:1504 Last updated: 08 AUG 2021 RESEARCH ARTICLE Computational genome-wide identification of heat shock protein genes in the bovine genome [version 1; peer review: 2 approved, 1 approved with reservations] Oyeyemi O. Ajayi1,2, Sunday O. Peters3, Marcos De Donato2,4, Sunday O. Sowande5, Fidalis D.N. Mujibi6, Olanrewaju B. Morenikeji2,7, Bolaji N. Thomas 8, Matthew A. Adeleke 9, Ikhide G. Imumorin2,10,11 1Department of Animal Breeding and Genetics, Federal University of Agriculture, Abeokuta, Nigeria 2International Programs, College of Agriculture and Life Sciences, Cornell University, Ithaca, NY, 14853, USA 3Department of Animal Science, Berry College, Mount Berry, GA, 30149, USA 4Departamento Regional de Bioingenierias, Tecnologico de Monterrey, Escuela de Ingenieria y Ciencias, Queretaro, Mexico 5Department of Animal Production and Health, Federal University of Agriculture, Abeokuta, Nigeria 6Usomi Limited, Nairobi, Kenya 7Department of Animal Production and Health, Federal University of Technology, Akure, Nigeria 8Department of Biomedical Sciences, Rochester Institute of Technology, Rochester, NY, 14623, USA 9School of Life Sciences, University of KwaZulu-Natal, Durban, 4000, South Africa 10School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, 30032, USA 11African Institute of Bioscience Research and Training, Ibadan, Nigeria v1 First published: 20 Sep 2018, 7:1504 Open Peer Review https://doi.org/10.12688/f1000research.16058.1 Latest published: 20 Sep 2018, 7:1504 https://doi.org/10.12688/f1000research.16058.1 Reviewer Status Invited Reviewers Abstract Background: Heat shock proteins (HSPs) are molecular chaperones 1 2 3 known to bind and sequester client proteins under stress. Methods: To identify and better understand some of these proteins, version 1 we carried out a computational genome-wide survey of the bovine 20 Sep 2018 report report report genome.
  • University of Groningen the Human HSP70/HSP40 Chaperone Family

    University of Groningen the Human HSP70/HSP40 Chaperone Family

    University of Groningen The human HSP70/HSP40 chaperone family Hageman, Jurre IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2008 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Hageman, J. (2008). The human HSP70/HSP40 chaperone family: a study on its capacity to combat proteotoxic stress. s.n. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne- amendment. Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 30-09-2021 CHAPTER 1 Introduction - Structural and functional diversities between members of the human HSPH, HSPA and DNAJ chaperone families Jurre Hageman and Harm H.
  • Identification and Characterization of TPRKB Dependency in TP53 Deficient Cancers

    Identification and Characterization of TPRKB Dependency in TP53 Deficient Cancers

    Identification and Characterization of TPRKB Dependency in TP53 Deficient Cancers. by Kelly Kennaley A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Molecular and Cellular Pathology) in the University of Michigan 2019 Doctoral Committee: Associate Professor Zaneta Nikolovska-Coleska, Co-Chair Adjunct Associate Professor Scott A. Tomlins, Co-Chair Associate Professor Eric R. Fearon Associate Professor Alexey I. Nesvizhskii Kelly R. Kennaley [email protected] ORCID iD: 0000-0003-2439-9020 © Kelly R. Kennaley 2019 Acknowledgements I have immeasurable gratitude for the unwavering support and guidance I received throughout my dissertation. First and foremost, I would like to thank my thesis advisor and mentor Dr. Scott Tomlins for entrusting me with a challenging, interesting, and impactful project. He taught me how to drive a project forward through set-backs, ask the important questions, and always consider the impact of my work. I’m truly appreciative for his commitment to ensuring that I would get the most from my graduate education. I am also grateful to the many members of the Tomlins lab that made it the supportive, collaborative, and educational environment that it was. I would like to give special thanks to those I’ve worked closely with on this project, particularly Dr. Moloy Goswami for his mentorship, Lei Lucy Wang, Dr. Sumin Han, and undergraduate students Bhavneet Singh, Travis Weiss, and Myles Barlow. I am also grateful for the support of my thesis committee, Dr. Eric Fearon, Dr. Alexey Nesvizhskii, and my co-mentor Dr. Zaneta Nikolovska-Coleska, who have offered guidance and critical evaluation since project inception.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • 1 Metabolic Dysfunction Is Restricted to the Sciatic Nerve in Experimental

    1 Metabolic Dysfunction Is Restricted to the Sciatic Nerve in Experimental

    Page 1 of 255 Diabetes Metabolic dysfunction is restricted to the sciatic nerve in experimental diabetic neuropathy Oliver J. Freeman1,2, Richard D. Unwin2,3, Andrew W. Dowsey2,3, Paul Begley2,3, Sumia Ali1, Katherine A. Hollywood2,3, Nitin Rustogi2,3, Rasmus S. Petersen1, Warwick B. Dunn2,3†, Garth J.S. Cooper2,3,4,5* & Natalie J. Gardiner1* 1 Faculty of Life Sciences, University of Manchester, UK 2 Centre for Advanced Discovery and Experimental Therapeutics (CADET), Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, UK 3 Centre for Endocrinology and Diabetes, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, UK 4 School of Biological Sciences, University of Auckland, New Zealand 5 Department of Pharmacology, Medical Sciences Division, University of Oxford, UK † Present address: School of Biosciences, University of Birmingham, UK *Joint corresponding authors: Natalie J. Gardiner and Garth J.S. Cooper Email: [email protected]; [email protected] Address: University of Manchester, AV Hill Building, Oxford Road, Manchester, M13 9PT, United Kingdom Telephone: +44 161 275 5768; +44 161 701 0240 Word count: 4,490 Number of tables: 1, Number of figures: 6 Running title: Metabolic dysfunction in diabetic neuropathy 1 Diabetes Publish Ahead of Print, published online October 15, 2015 Diabetes Page 2 of 255 Abstract High glucose levels in the peripheral nervous system (PNS) have been implicated in the pathogenesis of diabetic neuropathy (DN). However our understanding of the molecular mechanisms which cause the marked distal pathology is incomplete. Here we performed a comprehensive, system-wide analysis of the PNS of a rodent model of DN.
  • Mitochondrial Quality Control in Neurodegenerative Diseases: Focus on Parkinson’S Disease and Huntington’S Disease

    Mitochondrial Quality Control in Neurodegenerative Diseases: Focus on Parkinson’S Disease and Huntington’S Disease

    ADVERTIMENT. Lʼaccés als continguts dʼaquesta tesi queda condicionat a lʼacceptació de les condicions dʼús establertes per la següent llicència Creative Commons: http://cat.creativecommons.org/?page_id=184 ADVERTENCIA. El acceso a los contenidos de esta tesis queda condicionado a la aceptación de las condiciones de uso establecidas por la siguiente licencia Creative Commons: http://es.creativecommons.org/blog/licencias/ WARNING. The access to the contents of this doctoral thesis it is limited to the acceptance of the use conditions set by the following Creative Commons license: https://creativecommons.org/licenses/?lang=en Mitochondrial quality control in neurodegenerative diseases: focus on Parkinson’s disease and Huntington’s disease TESI DOCTORAL 2018 Programa de Doctorat en Neurociències Institut de Neurociències Tesi realitzada al laboratori de Malalties Neurodegeenratives de l’Institut de Recerca de la Vall d’Hebron (VHIR) Doctorand Director Tutor Sandra Franco Iborra Miquel Vila Bover José Rodríguez Álvarez Co-directora Co-directora Celine Perier Marta Martínez Vicente i AGRAÏMENTS En primer lloc vull agraïr al Miquel Vila per l’oportunitat que em va donar de començar a fer la tesi doctoral al seu lab. Gràcies per tenir sempre la porta oberta del teu despatx, per la confiança dipositada en mi i per tot el que m’has ensenyat durant tots aquests anys. A més, he tingut la sort de tenir no només un director de tesis sinó tres! Celine muchas gracias por estar siempre ahí, por ensenyarme tu manera de hacer ciencia (que me encanta!) y por ser siempre tan positiva. En mi manera de trabajar hay un poquito de ti y espero ir pasando este conocimiento a los demás porque en todo laboratorio debería ser obligatorio que hubiera alguien como tu.
  • Yeast Genome Gazetteer P35-65

    Yeast Genome Gazetteer P35-65

    gazetteer Metabolism 35 tRNA modification mitochondrial transport amino-acid metabolism other tRNA-transcription activities vesicular transport (Golgi network, etc.) nitrogen and sulphur metabolism mRNA synthesis peroxisomal transport nucleotide metabolism mRNA processing (splicing) vacuolar transport phosphate metabolism mRNA processing (5’-end, 3’-end processing extracellular transport carbohydrate metabolism and mRNA degradation) cellular import lipid, fatty-acid and sterol metabolism other mRNA-transcription activities other intracellular-transport activities biosynthesis of vitamins, cofactors and RNA transport prosthetic groups other transcription activities Cellular organization and biogenesis 54 ionic homeostasis organization and biogenesis of cell wall and Protein synthesis 48 plasma membrane Energy 40 ribosomal proteins organization and biogenesis of glycolysis translation (initiation,elongation and cytoskeleton gluconeogenesis termination) organization and biogenesis of endoplasmic pentose-phosphate pathway translational control reticulum and Golgi tricarboxylic-acid pathway tRNA synthetases organization and biogenesis of chromosome respiration other protein-synthesis activities structure fermentation mitochondrial organization and biogenesis metabolism of energy reserves (glycogen Protein destination 49 peroxisomal organization and biogenesis and trehalose) protein folding and stabilization endosomal organization and biogenesis other energy-generation activities protein targeting, sorting and translocation vacuolar and lysosomal
  • Roles of Extracellular Hsps As Biomarkers in Immune Surveillance and Immune Evasion

    Roles of Extracellular Hsps As Biomarkers in Immune Surveillance and Immune Evasion

    International Journal of Molecular Sciences Review Roles of Extracellular HSPs as Biomarkers in Immune Surveillance and Immune Evasion 1,2,3, 4, 1,5, , Eman A. Taha y, Kisho Ono y and Takanori Eguchi * y 1 Department of Dental Pharmacology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8525, Japan; [email protected] 2 Department of Medical Bioengineering, Graduate School of Natural Science and Technology, Okayama University, Okayama 700-8530, Japan 3 Department of Biochemistry, Ain Shams University Faculty of Science, Cairo 11566, Egypt 4 Department of Oral and Maxillofacial Surgery, Okayama University Hospital, Okayama 700-0914, Japan; [email protected] 5 Advanced Research Center for Oral and Craniofacial Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8525, Japan * Correspondence: [email protected]; Tel.: +81-86-235-6662 These authors contributed equally to this work. y Received: 16 August 2019; Accepted: 14 September 2019; Published: 17 September 2019 Abstract: Extracellular heat shock proteins (ex-HSPs) have been found in exosomes, oncosomes, membrane surfaces, as well as free HSP in cancer and various pathological conditions, also known as alarmins. Such ex-HSPs include HSP90 (α, β, Gp96, Trap1), HSP70, and large and small HSPs. Production of HSPs is coordinately induced by heat shock factor 1 (HSF1) and hypoxia-inducible factor 1 (HIF-1), while matrix metalloproteinase 3 (MMP-3) and heterochromatin protein 1 are novel inducers of HSPs. Oncosomes released by tumor cells are a major aspect of the resistance-associated secretory phenotype (RASP) by which immune evasion can be established.
  • Supplemental Information

    Supplemental Information

    Supplemental information Dissection of the genomic structure of the miR-183/96/182 gene. Previously, we showed that the miR-183/96/182 cluster is an intergenic miRNA cluster, located in a ~60-kb interval between the genes encoding nuclear respiratory factor-1 (Nrf1) and ubiquitin-conjugating enzyme E2H (Ube2h) on mouse chr6qA3.3 (1). To start to uncover the genomic structure of the miR- 183/96/182 gene, we first studied genomic features around miR-183/96/182 in the UCSC genome browser (http://genome.UCSC.edu/), and identified two CpG islands 3.4-6.5 kb 5’ of pre-miR-183, the most 5’ miRNA of the cluster (Fig. 1A; Fig. S1 and Seq. S1). A cDNA clone, AK044220, located at 3.2-4.6 kb 5’ to pre-miR-183, encompasses the second CpG island (Fig. 1A; Fig. S1). We hypothesized that this cDNA clone was derived from 5’ exon(s) of the primary transcript of the miR-183/96/182 gene, as CpG islands are often associated with promoters (2). Supporting this hypothesis, multiple expressed sequences detected by gene-trap clones, including clone D016D06 (3, 4), were co-localized with the cDNA clone AK044220 (Fig. 1A; Fig. S1). Clone D016D06, deposited by the German GeneTrap Consortium (GGTC) (http://tikus.gsf.de) (3, 4), was derived from insertion of a retroviral construct, rFlpROSAβgeo in 129S2 ES cells (Fig. 1A and C). The rFlpROSAβgeo construct carries a promoterless reporter gene, the β−geo cassette - an in-frame fusion of the β-galactosidase and neomycin resistance (Neor) gene (5), with a splicing acceptor (SA) immediately upstream, and a polyA signal downstream of the β−geo cassette (Fig.
  • Structure of an Auxilin-Bound Clathrin Coat and Its Implications for The

    Structure of an Auxilin-Bound Clathrin Coat and Its Implications for The

    letters to nature common drug target27, suggesting that the spindle-associated 24. Chi, N. W. & Lodish, H. F. Tankyrase is a golgi-associated mitogen-activated protein kinase substrate A that interacts with IRAP in GLUT4 vesicles. J. Biol. Chem. 275, 38437–38444 (2000). PARPs are potential cancer drug targets. 25. Rouleau, M., Aubin, R. A. & Poirier, G. G. Poly(ADP-ribosyl)ated chromatin domains: access granted. J. Cell Sci. 117, 815–825 (2004). Methods 26. Pickett-Heaps, J. D., Forer, A. & Spurck, T. Traction fibre: toward a “tensegral” model of the spindle. Cell Motil. Cytoskel. 37, 1–6 (1997). Imaging and antibodies 27. Troll, W., Garte, S. & Frenkel, K. Suppression of tumor promotion by inhibitors of poly(ADP)ribose Cycled Xenopus egg extract spindles were assembled as described12 with or without formation. Basic Life Sci. 52, 225–232 (1990). X-rhodamine-labelled or Alexa-488-labelled tubulin, and isolated through 40% glycerol 28. Tirnauer, J. S., Salmon, E. D. & Mitchison, T. J. Microtubule plus-end dynamics in Xenopus egg extract BRB80. For staining of non-fixed spindles, isolated spindles were processed for spindles. Mol. Biol. Cell 15, 1776–1784 (2004). immunofluorescence in solutions containing 5% glycerol BRB80. For 29. Lin, W., Ame, J. C., Aboul-Ela, N., Jacobson, E. L. & Jacobson, M. K. Isolation and characterization of immunofluorescence and immunoblotting, polyclonal rabbit LP96-10 IgG was purchased the cDNA encoding bovine poly(ADP-ribose) glycohydrolase. J. Biol. Chem. 272, 11895–11901 from BD Biosciences, polyclonal chicken IgYanti-PAR antibodies from Tulip Biolabs, and (1997). monoclonal 10H from Trevigen. All anti-PAR antibodies were pre-adsorbed against BSA transferred to nitrocellulose.
  • 140503 IPF Signatures Supplement Withfigs Thorax

    140503 IPF Signatures Supplement Withfigs Thorax

    Supplementary material for Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis Daryle J. DePianto1*, Sanjay Chandriani1⌘*, Alexander R. Abbas1, Guiquan Jia1, Elsa N. N’Diaye1, Patrick Caplazi1, Steven E. Kauder1, Sabyasachi Biswas1, Satyajit K. Karnik1#, Connie Ha1, Zora Modrusan1, Michael A. Matthay2, Jasleen Kukreja3, Harold R. Collard2, Jackson G. Egen1, Paul J. Wolters2§, and Joseph R. Arron1§ 1Genentech Research and Early Development, South San Francisco, CA 2Department of Medicine, University of California, San Francisco, CA 3Department of Surgery, University of California, San Francisco, CA ⌘Current address: Novartis Institutes for Biomedical Research, Emeryville, CA. #Current address: Gilead Sciences, Foster City, CA. *DJD and SC contributed equally to this manuscript §PJW and JRA co-directed this project Address correspondence to Paul J. Wolters, MD University of California, San Francisco Department of Medicine Box 0111 San Francisco, CA 94143-0111 [email protected] or Joseph R. Arron, MD, PhD Genentech, Inc. MS 231C 1 DNA Way South San Francisco, CA 94080 [email protected] 1 METHODS Human lung tissue samples Tissues were obtained at UCSF from clinical samples from IPF patients at the time of biopsy or lung transplantation. All patients were seen at UCSF and the diagnosis of IPF was established through multidisciplinary review of clinical, radiological, and pathological data according to criteria established by the consensus classification of the American Thoracic Society (ATS) and European Respiratory Society (ERS), Japanese Respiratory Society (JRS), and the Latin American Thoracic Association (ALAT) (ref. 5 in main text). Non-diseased normal lung tissues were procured from lungs not used by the Northern California Transplant Donor Network.